Relationship Between Gut Microbiota Dysbiosis and Cardiometabolic Diseases Based on "Heart-spleen-intestine" Axis
10.13422/j.cnki.syfjx.20241065
- VernacularTitle:基于“心-脾-肠”轴探讨肠道菌群紊乱与代谢性心血管病的关系
- Author:
Qian XU
1
;
Wenting WANG
1
;
Yiwen LI
2
;
Jing CUI
1
;
Mengmeng ZHU
1
;
Yanfei LIU
1
;
Yue LIU
1
Author Information
1. National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine， Xiyuan Hospital of China Academy of Chinese Medical Sciences，Beijing 100091，China
2. Experimental Research Center，China Academy of Chinese Medical Sciences，Beijing 100700，China
- Publication Type:Journal Article
- Keywords:
cardiometabolic diseases;
gut microbiota;
"heart-spleen-intestine" axis;
traditional Chinese medicine（TCM）;
integrated traditional Chinese and western medicine;
metabolic regulation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(20):203-211
- CountryChina
- Language:Chinese
-
Abstract:
Cardiometabolic disease is a clinical syndrome with a causal relationship between metabolic abnormalities and cardiovascular damage. With its global incidence and related mortality rates continually rising， it has become a major health concern worldwide. The role of the gut microbiome and its metabolic products in cardiovascular metabolic health has received widespread attention， with gut microbiota dysbiosis considered a key factor in promoting the development of cardiometabolic disease. Dysbiosis disrupts the balance of the "heart-spleen-intestine" axis， leading to dysfunction of the spleen and intestines， which triggers metabolic disorders and accelerates the progression of cardiometabolic disease. Cardiac dysfunction can also negatively affect spleen and intestinal function， leading to imbalances in the heart and spleen， disharmony in Qi and blood， and exacerbating metabolic anomalies and further dysbiosis， thus forming a vicious cycle. From a modern biological perspective， the gut microbiome and its metabolic products can influence disease progression by modulating inflammatory responses and immune imbalances， leading to endothelial dysfunction and metabolic disorders， thereby increasing the risk of cardiometabolic disease. Additionally， the article proposes strategies for managing cardiometabolic disease by regulating the gut microbiome through a combination of Chinese and western medicine approaches. Traditional Chinese medicine（TCM） treatment starts from the gut microbiome， using the "heart-spleen-intestine" axis as a mediator to regulate cardiovascular metabolic health， highlighting the unique advantages of TCM in targeting the gut microbiome to treat cardiometabolic disease. This article takes the TCM theory of the "heart-spleen-intestine" axis as a starting point， discusses the pivotal role played by this axis in the connection between gut microbiome dysbiosis and the development of cardiometabolic disease， aiming to provide a new perspective for the integrated traditional Chinese and western medical research on cardiometabolic disease， offering scientific evidence and practical guidance to improve the prognosis and quality of life for patients.
